Guardant Health, Inc. (NASDAQ:GH) Short Interest Update

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 9,560,000 shares, an increase of 25.1% from the March 31st total of 7,640,000 shares. Based on an average daily trading volume, of 1,990,000 shares, the short-interest ratio is presently 4.8 days.

Insider Activity at Guardant Health

In related news, insider Kumud Kalia bought 2,187 shares of the stock in a transaction dated Monday, March 18th. The stock was bought at an average cost of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now owns 12,722 shares of the company's stock, valued at $226,706.04. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 6.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. raised its holdings in shares of Guardant Health by 2.8% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 16,854 shares of the company's stock worth $500,000 after buying an additional 453 shares in the last quarter. Amalgamated Bank boosted its position in Guardant Health by 3.2% during the third quarter. Amalgamated Bank now owns 17,058 shares of the company's stock valued at $506,000 after acquiring an additional 521 shares during the last quarter. CWM LLC grew its stake in Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company's stock worth $29,000 after purchasing an additional 569 shares during the period. Van ECK Associates Corp grew its holdings in Guardant Health by 29.4% in the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company's stock worth $73,000 after purchasing an additional 614 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its stake in Guardant Health by 2.1% in the third quarter. State Board of Administration of Florida Retirement System now owns 32,238 shares of the company's stock valued at $956,000 after acquiring an additional 670 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Stock Down 1.0 %

Shares of NASDAQ:GH traded down $0.19 during midday trading on Tuesday, reaching $18.00. The company had a trading volume of 1,168,510 shares, compared to its average volume of 1,865,512. Guardant Health has a 1-year low of $15.81 and a 1-year high of $41.06. The stock has a market cap of $2.19 billion, a PE ratio of -4.21 and a beta of 0.87. The company has a quick ratio of 6.24, a current ratio of 6.54 and a debt-to-equity ratio of 7.18. The business's 50 day moving average price is $18.65 and its 200 day moving average price is $22.75.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.65). The business had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. Research analysts forecast that Guardant Health will post -3.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of recent analyst reports. Guggenheim restated a "neutral" rating on shares of Guardant Health in a research note on Friday, April 5th. Canaccord Genuity Group reduced their price target on shares of Guardant Health from $45.00 to $30.00 and set a "buy" rating for the company in a research note on Monday. JPMorgan Chase & Co. dropped their target price on Guardant Health from $60.00 to $45.00 and set an "overweight" rating on the stock in a report on Friday, February 23rd. The Goldman Sachs Group lowered their target price on Guardant Health from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, April 15th. Finally, Craig Hallum started coverage on Guardant Health in a report on Wednesday, April 24th. They issued a "buy" rating and a $28.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Guardant Health presently has a consensus rating of "Moderate Buy" and an average target price of $37.91.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.